Botulinum toxin is a toxin emitted by some animals which can cause paralysis. But its medical benefits which include cosmetic treatment to deter aging have led to increased interest in this chemical.
Botulinum Toxin
Botulinum toxin (BNT) is a neurotoxin drug produced by Clostridium botulinum, an anaerobic bacterium. It has seven different forms namely – A, B, C, D, E, F, and G. Out of these, only A and B are commercially produced as drugs. Various products based on BNTA are “Dysport” and “Botox”. “Myobloc”, a BNTB product by Solstice Neurosciences, LLC is only available in Germany due to its high cost and poor coverage under medical insurance.
BNT has many off-label uses due to its legal complications. For instance, it can only be used to treat neurological conditions in Germany. But the same drug is available to treat the glabella under the name of Vistabel. The glabella is the most frequent area for Botox injections. Some side-effects of BNT include nausea, allergic reactions, and shortness of breath.
Developments
Although the toxin is most prominent for cosmetic uses, it can be used for treating various disorders and conditions. People with excessive sweating and chronic migraine can find relief from BNT. Men in Australia are being treated with Botox injections for excessive sweating or hyperhydrosis. It peaks commonly between the ages of 18 to 54. It is estimated to affect nearly 3% of Australians. The shots are delivered every four months to each armpit to control the sweating.
Ipsen, a French pharmaceutical company, has collaborated with EpiVax, Inc. to develop new BNT-based products and Targeted Secretion Inhibitor (TSI) therapeutics. Epivax is developing a new BNT sequence with the help of their proprietary “Interactive Screening and Protein Reengineering Interface” (ISPRI) system. Ipsen recently got U.S. FDA approval for using “Dysport” to treat lower limb spasticity in pediatrics.
Market Overview
The botulinum toxin market size can touch USD 7.3 billion by 2025, according to Grand View Research, Inc. Demand of minimally invasive and non-invasive aesthetic procedures are driving market growth. BNTA obtained large market shares in 2015 on account of its capacity to treat glabellar lines and blepharospasm.
Aesthetic and therapeutic uses are major market applications. Out of these, aesthetic use had higher market shares in 2015. But therapeutic use segment can gain a windfall in the coming years. North America market dominated globally on the basis of revenue in 2015Some prominent industry players are Allergan, Inc.; Revance Therapeutics, Inc.; and Ipsen Group.
In-Depth research report on botulinum toxin market:
No comments:
Post a Comment